Welcome to our dedicated page for Veraxa Biotech news (Ticker: VRXA), a resource for investors and traders seeking the latest updates and insights on Veraxa Biotech stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Veraxa Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Veraxa Biotech's position in the market.
VERAXA Biotech (NASDAQ: VRXA) reported significant strengthening of its intellectual property in H1 2026, filing the first BiTAC-related patent applications covering composition of matter and its proprietary payload platform for BiTAC-TCE and BiTAC-ADC technologies and derived programs.
The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with additional auxiliary technology patents clearing opposition periods. Once newly filed applications are granted, VERAXA expects protection of its core technology suite, including click chemistry, conjugation, linker and payload innovations, through at least 2047.
VERAXA Biotech (NASDAQ: VRXA) announced that bispecific antibody-drug conjugate program VXA-222, originating from its May 2025 alliance with OmniAb (NASDAQ: OABI), has achieved a key technical milestone and is advancing into the next collaboration phase as OmniAb’s discovery work has concluded.
VXA-222 is a bispecific ADC using an “AND-gate” design to target two antigens on solid tumors in a single molecule. VERAXA used OmniAb’s transgenic antibody discovery technologies, including OmniClic, to generate antibody leads and will now apply its proprietary linker and conjugation technology, and conduct in vitro and in vivo validation. VERAXA holds exclusive development and commercialization rights to products using OmniAb-derived antibodies, while OmniAb is entitled to a share of specified revenue from such products.
VERAXA Biotech (NASDAQ: VRXA) reported that shareholders at its Extraordinary General Meeting on July 24, 2026 approved all Board proposals, with more than 99.94% of represented votes in favor. A total of 102,102,301 voting shares, equal to 72.20% of share capital, were represented.
The resolutions introduce conditional share capital for shareholder options and warrants, establish a capital band through December 31, 2030, and increase the maximum Board size from five to seven members. According to VERAXA, these changes are intended to enhance its corporate and financing flexibility to support acquisitions, strategic collaborations, capital markets activities, and continued investment in its BiTAC technology platform and oncology pipeline.
VERAXA Biotech (NASDAQ: VRXA) has appointed Christoph Erkel, Ph.D., as Chief Scientific Officer, effective immediately, succeeding Rick Austin, Ph.D., who will leave after a transition period. Erkel, previously Vice President of R&D at VERAXA, will lead development of the company’s proprietary BiTAC® bi-targeted tumor-associated cytotoxicity technology platforms to pursue safer, more effective therapies for solid tumors.
According to VERAXA, Erkel brings 20 years of antibody therapeutics experience spanning antibody engineering, discovery and preclinical development up to IND submission, including leadership roles at MorphoSys and Sloning BioTechnology. The company is advancing a pipeline of T cell engagers, bispecific ADCs and proprietary BiTAC formats toward clinical development.
VERAXA Biotech (NASDAQ: VRXA) reported that Germany’s Paul-Ehrlich-Institute (PEI) provided Scientific Advice on the biological rationale and non-clinical development plan for its lead BiTAC-TCE program. The feedback supports VERAXA’s dual-targeting, conditionally active BiTAC-TCE format and offers initial de-risking and greater clarity for its development strategy.
According to VERAXA, preclinical data presented at AACR 2026 showed the BiTAC-TCE candidate selectively attacked cancer cells expressing both targets, spared single-target cells, and achieved a superior safety profile with similar efficacy versus a traditional TCE, suggesting a potentially improved therapeutic index.
VERAXA Biotech (NASDAQ: VRXA) announced a collaboration with Ardigen, an AI-focused computational R&D partner, to support VERAXA’s expanding BiTAC® pipeline of T cell engagers (TCEs) and antibody drug conjugates (ADCs). The partnership aims to integrate Ardigen’s platform with VERAXA’s in-house AI to optimize dual cancer target selection for conditionally active therapies.
BiTAC-TCEs and planned BiTAC-ADCs employ a Boolean “AND-gate” logic, requiring co-expression of two targets on the same cancer cell for activation, which VERAXA believes may widen the therapeutic window and reduce on-target, off-tumor toxicity. Initial work will develop AI-enabled tools and models to identify synergistic cancer target pairs, leveraging large preclinical and clinical datasets, including programs that failed due to toxicity despite promising efficacy.
VERAXA Biotech (NASDAQ: VRXA) has appointed Carl von Halem as Interim Chief Financial Officer, succeeding Torsten Bürgermeister, effective July 10, 2026. VERAXA is in late-stage discussions with a permanent successor to support its next phase of expansion and operational growth.
According to VERAXA, von Halem, currently CFO of Xlife Science and Managing Director of Xlife Science GmbH, played a key role in taking VERAXA public and has deep knowledge of its operations, strategy, and structure. He also serves on boards of Xlife Science portfolio companies and has prior experience in fintech and renewable energy.
VERAXA Biotech (NASDAQ: VRXA) issued a business update highlighting its focus on novel BiTAC®-based cancer therapies and partnering plans. The company is prioritizing BiTAC T cell engagers and bispecific ADCs, intends to monetize non-BiTAC assets, and aims to have lead BiTAC-TCE candidate VXA-102 IND/CTA-ready by early 2028.
VERAXA currently has four BiTAC-based T cell engager programs for solid tumors and two bispecific ADC programs, including a partnered bsADC with OmniAb. Antibody VXA-901 for AML and a HER2-targeting ADC are available for partnering amid strong industry interest in TCE and ADC technologies.
VERAXA Biotech (NASDAQ: VRXA) has initiated cell line development for its lead BiTAC T‑cell engager (BiTAC‑TCE), engaging ATUM to apply its Leap-In Transposase technology. This collaboration supports generation of stable clonal cell lines, a key step toward IND/CTA‑enabling activities and future clinical development of VERAXA’s most advanced BiTAC‑TCE candidate.
VERAXA Biotech (NASDAQ: VRXA) expanded its R&D hub in Heidelberg, increasing laboratory space by more than 60%. The added space supports planned R&D team growth, new lab equipment, and full R&D infrastructure build-out.
The expansion backs VERAXA’s proprietary BiTAC™-TCE and BiTAC™-ADC cancer therapy programs as they move toward early clinical development.